You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Interim results from a study in the Netherlands suggest whole-genome sequencing can be done fast enough to uncover treatment targets in metastatic cancer patients.
Using proteomic, phosphoproteomic, and genomic data, researchers uncovered informative features in primary and metastatic samples from almost 150 CRC cases in China.
Transcription factor reprogramming during prostate cancer metastases appears to involve epigenetic changes that resemble those at play during prostate development, new research finds.
While a subset of metastatic castration-resistant tumors was marked by enhanced methylation, the analysis also pointed to recurrently hypomethylated regions.
Lexent's technology integrates low-pass whole-genome sequencing, fragmentomics, and DNA methylation to detect early stage disease.
Presentations at the American Society of Clinical Oncology's virtual annual meeting included new findings relevant to both blood- and spinal fluid-based approaches.
The study found that metastatic seeding may occur early in primary tumor development, and treatment of metastases may fuel many of their mutations.
An analysis of lung adenocarcinoma brain metastases uncovered more frequent amplifications or deletions in a handful of genomic regions, pointing to potential drivers.
Tumor genomes from almost 2,400 patients with metastatic cancer revealed a range of somatic alterations, providing a foundation for clinical sequencing efforts.
The team identified six independent DNA methylation blocks that could potentially help to predict the formation of central nervous system metastases in lung cancer.
The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.
A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.
NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.
In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.